Jaafar Bennouna
Overview
Explore the profile of Jaafar Bennouna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
12055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pons-Tostivint E, de Decker L, Haudebert G, Hulo P, Chen J, Bennouna J, et al.
Bull Cancer
. 2024 Mar;
111(6):566-575.
PMID: 38485628
Introduction: The number of Advanced Practice Nurses (APNs) has significantly increased in France since 2019, with the number of graduates expected to reach 1700 by the end of 2023, up...
12.
Mathiot L, Nigen B, Goronflot T, Hiret S, Doucet L, Pons-Tostivint E, et al.
Clin Lung Cancer
. 2024 Jan;
25(3):244-253.e2.
PMID: 38218680
Background: The prognostic impact of TP53 mutations in advanced or metastatic nonsquamous non-small-cell lung cancer (nsNSCLC) patients treated with chemotherapy and/or immune checkpoint inhibitors (ICI) remains unclear. Materials And Methods:...
13.
Porte M, Vaudron A, Crequit P, Vaugier L, Chatellier T, Fronteau C, et al.
Clin Lung Cancer
. 2023 Dec;
25(2):e101-e111.e2.
PMID: 38072729
Background: First-line chemotherapy plus immunotherapy (CT-IO) has recently demonstrated survival benefits over CT alone in extensive-stage small-cell lung cancer (ES-SCLC), based on randomized phase III studies. This retrospective multicenter study...
14.
Tan D, Felip E, de Castro G, Solomon B, Greystoke A, Cho B, et al.
J Clin Oncol
. 2023 Dec;
42(2):192-204.
PMID: 38039427
Purpose: The addition of checkpoint inhibitors to first-line treatment has prolonged survival of patients with non-small-cell lung cancer (NSCLC), but prognosis remains poor, with new treatment options needed. Canakinumab, a...
15.
Taieb J, Bennouna J, Penault-Llorca F, Basile D, Samalin E, Zaanan A
Eur J Cancer
. 2023 Nov;
195:113370.
PMID: 37948843
Gastric adenocarcinoma (GC) and gastroesophageal junction adenocarcinoma represent frequent and severe diseases whose management has radically changed over the last 10 years. With the advent of second- and third-line standard...
16.
Stoekle H, Billard D, Bennouna J, Beuzeboc P, Herve C
J Transl Med
. 2023 Oct;
21(1):767.
PMID: 37904183
No abstract available.
17.
Stoekle H, Sekkate S, Ayoubi J, Bennouna J, Beuzeboc P, Herve C
Hum Vaccin Immunother
. 2023 Oct;
19(3):2266935.
PMID: 37822281
No abstract available.
18.
Rasola C, Laurent-Puig P, Andre T, Falcoz A, Lepage C, Aparicio T, et al.
Eur J Cancer
. 2023 Oct;
194:113321.
PMID: 37797388
Background: It is intuitively thought that early relapse is associated with poor survival after recurrence (SAR) in resected colon cancer (CC) patients, but this has never been formally studied. Methods:...
19.
Nigen B, Goronflot T, Herbreteau G, Mathiot L, Sagan C, Raimbourg J, et al.
Lung Cancer
. 2023 Aug;
184:107321.
PMID: 37586178
Background: Although brain metastases (BM) at diagnosis are common in non-squamous NSCLC patients (ns-NSCLC), they have been mostly excluded from randomized trials. The aim of this retrospective study was to...
20.
Thibaudin M, Fumet J, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, et al.
Nat Med
. 2023 Aug;
29(8):2087-2098.
PMID: 37563240
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single-arm,...